[go: up one dir, main page]

CO5611134A2 - Composiciones farmaceuticas que contienen sales de tiotropio y nuevos agentes inhibidores de la cinasa egfr - Google Patents

Composiciones farmaceuticas que contienen sales de tiotropio y nuevos agentes inhibidores de la cinasa egfr

Info

Publication number
CO5611134A2
CO5611134A2 CO04090723A CO04090723A CO5611134A2 CO 5611134 A2 CO5611134 A2 CO 5611134A2 CO 04090723 A CO04090723 A CO 04090723A CO 04090723 A CO04090723 A CO 04090723A CO 5611134 A2 CO5611134 A2 CO 5611134A2
Authority
CO
Colombia
Prior art keywords
salts
egfr
possibly
tiotropal
cinase
Prior art date
Application number
CO04090723A
Other languages
English (en)
Inventor
Birgit Jung
Michel Pairet
Michael Pairet
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of CO5611134A2 publication Critical patent/CO5611134A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

1.- Medicamento, caracterizado por un cierto contenido de uno o varios agentes anticolinérgicos (1) en combinación con uno o varios agentes inhibidores de la cinasa del EGFR (2) eventualmente en forma de sus enantiómeros, de mezclas de los enantiómeros o en forma de los racematos, eventualmente en forma de los solvatos o hidratos así como eventualmente en común con una sustancia auxiliar farmacéuticamente compatible.2.- Medicamento según la reivindicación 1, caracterizado porque las sustancias activas 1 y 2 están contenidas ya sea en común en una forma de presentación o en dos formas de presentación separadas.3.- Medicamento según una de las reivindicaciones 1 ó 2, caracterizado porque la sustancia activa 1 se selecciona entre el conjunto que consta de sales de tiotropio, sales de oxitropio o sales de ipratropio, de un modo preferido sales de tiotropio.4.- Medicamento según una de las reivindicaciones 1 a 3, caracterizado porque la sustancia activa 1 está contenida en forma del cloruro, bromuro, yoduro, metano-sulfonato, para-tolueno-sulfonato o metil-sulfato, de un modo preferido en forma del bromuro.
CO04090723A 2002-02-16 2004-09-13 Composiciones farmaceuticas que contienen sales de tiotropio y nuevos agentes inhibidores de la cinasa egfr CO5611134A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10206505A DE10206505A1 (de) 2002-02-16 2002-02-16 Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und EGFR-Kinase-Hemmern

Publications (1)

Publication Number Publication Date
CO5611134A2 true CO5611134A2 (es) 2006-02-28

Family

ID=27635037

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04090723A CO5611134A2 (es) 2002-02-16 2004-09-13 Composiciones farmaceuticas que contienen sales de tiotropio y nuevos agentes inhibidores de la cinasa egfr

Country Status (21)

Country Link
EP (1) EP1478398B1 (es)
JP (1) JP2005517039A (es)
KR (1) KR20040083519A (es)
CN (1) CN1633305A (es)
AR (1) AR038494A1 (es)
AT (1) ATE430581T1 (es)
AU (1) AU2003206881B2 (es)
BR (1) BR0307703A (es)
CA (1) CA2476127C (es)
CO (1) CO5611134A2 (es)
DE (2) DE10206505A1 (es)
ES (1) ES2326968T3 (es)
MX (1) MXPA04007813A (es)
NZ (1) NZ535166A (es)
PE (1) PE20030859A1 (es)
PL (1) PL369736A1 (es)
RU (1) RU2004127869A (es)
TW (1) TW200400036A (es)
UY (1) UY27670A1 (es)
WO (1) WO2003068264A1 (es)
ZA (1) ZA200404787B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230751A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und EGFR-Kinase-Hemmern
HRP20080329T3 (en) 2003-09-16 2008-08-31 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
DE102004001607A1 (de) * 2004-01-09 2005-08-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen auf der Basis von Scopin- oder Tropensäureestern mit EGFR-Kinase-Hemmern
US20060035893A1 (en) * 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
AU2006288716A1 (en) * 2005-09-06 2007-03-15 T.K. Signal Ltd. Polyalkylene glycol derivatives of 4- (phenylamino)quinazolines useful as irreversible inhibitors of epidermal growth factor receptor tyrosine kinase
KR100832594B1 (ko) * 2005-11-08 2008-05-27 한미약품 주식회사 다중저해제로서의 퀴나졸린 유도체 및 이의 제조방법
TWI385174B (zh) 2008-11-10 2013-02-11 Nat Health Research Institutes 作為酪胺酸激酶抑制劑之稠合雙環及多環嘧啶化合物
US20120220557A1 (en) * 2011-02-17 2012-08-30 Chiesi Farmaceutici S.P.A. Liquid propellant-free formulation comprising an antimuscarinic drug
US10710968B2 (en) 2016-01-13 2020-07-14 Hadasit Medical Research Services And Development Ltd. Radiolabeled erlotinib analogs and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042062A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung

Also Published As

Publication number Publication date
NZ535166A (en) 2007-01-26
EP1478398B1 (de) 2009-05-06
WO2003068264A1 (de) 2003-08-21
RU2004127869A (ru) 2005-08-27
BR0307703A (pt) 2005-01-04
DE10206505A1 (de) 2003-08-28
AU2003206881B2 (en) 2009-02-26
ATE430581T1 (de) 2009-05-15
UY27670A1 (es) 2003-09-30
AU2003206881A1 (en) 2003-09-04
ZA200404787B (en) 2005-08-11
CA2476127A1 (en) 2003-08-21
DE50311496D1 (de) 2009-06-18
MXPA04007813A (es) 2004-10-15
EP1478398A1 (de) 2004-11-24
KR20040083519A (ko) 2004-10-02
TW200400036A (en) 2004-01-01
PE20030859A1 (es) 2003-11-18
CA2476127C (en) 2011-06-14
ES2326968T3 (es) 2009-10-22
CN1633305A (zh) 2005-06-29
PL369736A1 (en) 2005-05-02
AR038494A1 (es) 2005-01-19
JP2005517039A (ja) 2005-06-09

Similar Documents

Publication Publication Date Title
AR039273A1 (es) Composiciones farmaceuticas basadas en anticolinergicos e inhibidores de la p38 quinasa
EA200702498A1 (ru) N-(пиридин-2-ил)сульфонамидные производные
MX2023012361A (es) Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo.
UY29246A1 (es) Nuevos compuestos
ECSP078003A (es) Inhibidores de aspartil proteasas
PA8587101A1 (es) Nuevos derivados de dihidropirimido [4,5-d] pirimidinona sustituida por amiino, fabricacion y uso de los mismos como agentes farmaceuticos
UY27446A1 (es) Nuevos compuestos
PA8586401A1 (es) 4-piperazinilbencenosulfonilindoles y uso de los mismos
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
PE20081649A1 (es) Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos
AR047823A1 (es) Derivados de 1,2,3,4-tetrahidroisoquinolina sustituida
CO5611134A2 (es) Composiciones farmaceuticas que contienen sales de tiotropio y nuevos agentes inhibidores de la cinasa egfr
ECSP088971A (es) Ligandos 101 de los receptores nicotínicos de acetilcolina
ECSP088549A (es) Nuevos derivados de pirrol fusionado
TW200635897A (en) Piperidine derivatives and their use as anti-inflammatory agents
CL2008003284A1 (es) Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras.
AR035417A1 (es) Derivados triciclicos de lactama y sultama, procesos para su elaboracion, medicamentos que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
AR064619A1 (es) Derivados de amino-imidazopiridinas, composiciones farmaceuticas que los contienen y usos de los mismos como agentes antitumorales.
ES2187983T3 (es) Derivados 1,2,3,4-tetrahidronaftaleno sustituidos.
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
SV2005002099A (es) " nuevos compuestos " ref. pc 32096a
UY25044A1 (es) Utilizacion de inhibidores selectivos directos o indirectos del factor xa solos o en combinacion con un compuesto antiagregante plaquetario y composiciones destinadas a prevenir y tratar las enfermedades tromboembólicas arteriales
PA8589601A1 (es) Derivados de indazol como antagonistas del crf
AR054688A1 (es) Alquil-piridinas como inhibidores 11-beta de la diabetes
UY38994A (es) Compuestos activos frente a receptores nucleares

Legal Events

Date Code Title Description
FG Application granted